Cellegy Pharmaceuticals Announces Completion Of Asset Sale To ProStrakan Group

Published: Nov 29, 2006

QUAKERTOWN, Pa., Nov. 28 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. , a specialty pharmaceutical company, announced today the completion of the sale to Strakan International Limited, a wholly owned subsidiary of ProStrakan Group plc , a publicly-traded pharmaceutical company based in the United Kingdom, of Cellegy's rights to Cellegesic(TM) (nitroglycerin ointment), which is branded Rectogesic outside of the United States, Fortigel(TM) (testosterone gel), Tostrex(TM) (testosterone gel) and Tostrelle(R) (testosterone gel), and related intellectual property assets. ProStrakan also assumed various existing distribution and other agreements, including in certain Southeast Asian countries, relating to the assets and intellectual property that was sold. The signing of the asset purchase agreement was originally announced on September 27, 2006, and Cellegy's stockholders approved the transaction at a special meeting of stockholders held on November 22, 2006.

The aggregate purchase price was $9 million. From the sales proceeds, Cellegy paid ProStrakan approximately $2 million in repayment of a loan that ProStrakan had made to Cellegy at the time the asset purchase agreement was signed. Cellegy also paid $2,625,000 from the proceeds to PDI, Inc. and Neptune Pharmaceutical Corporation in final settlement of Cellegy's obligations under previous agreements with those companies.

Cellegy Pharmaceuticals, Inc.

CONTACT: Richard C. Williams, Chairman and Interim CEO, +1-215-529-6084,or Robert J. Caso, Vice President, Finance & CFO, +1-215-529-6084, both ofCellegy Pharmaceuticals, Inc.

Back to news